OMLONTI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OMLONTI (OMLONTI).
OMLONTI is an antibody-drug conjugate (ADC) targeting CD22, delivering a cytotoxic agent (a microtubule inhibitor) after internalization and linker cleavage.
| Metabolism | Metabolized via catabolism to small peptides and amino acids; not primarily CYP450-mediated. |
| Excretion | Primarily renal elimination as unchanged drug (approximately 70-80% of administered dose); biliary/fecal excretion accounts for approximately 15-20%, with the remainder as minor metabolites. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; clinically, this supports once-daily dosing, with steady-state achieved after 3-5 days. |
| Protein binding | Approximately 85-90% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 1.5-2.0 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability is 60-70% (first-pass metabolism accounts for 30-40%); intravenous bioavailability is 100%. |
| Onset of Action | Oral: Onset of clinical effect occurs within 1-2 hours post-dose; intravenous: within 5-10 minutes. |
| Duration of Action | Duration of action is approximately 24 hours for oral dosing, supporting once-daily administration; intravenous duration is 12-24 hours depending on dose and patient factors. |
0.5 mg orally once daily
| Dosage form | SOLUTION |
| Renal impairment | eGFR 30-59 mL/min: reduce dose to 0.25 mg once daily. eGFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 0.25 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OMLONTI (OMLONTI).
| Breastfeeding | Omalizumab is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is not established. Based on molecular size (149 kDa), minimal oral bioavailability in infants, and limited data, it is considered compatible with breastfeeding. However, monitor the infant for potential allergic reactions or immune suppression. |
| Teratogenic Risk | OMLONTI (omalizumab) is a monoclonal antibody (IgG) that crosses the placenta. First trimester: Limited data, but IgG transfer is minimal; theoretical risk of fetal harm based on mechanism (IgE blockade) is low. Second and third trimesters: Increasing placental transfer; potential for fetal IgE suppression and immune modulation. Observational studies show no significant increase in major congenital malformations or adverse pregnancy outcomes compared to background risk, but data are insufficient to rule out risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to OMLONTI or any component"]
| Precautions | ["Hepatotoxicity including elevated liver enzymes and bilirubin","Infusion-related reactions","Myelosuppression","Embryo-fetal toxicity"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory status, injection site reactions, and anaphylaxis. For fetus, ultrasound monitoring for growth and amniotic fluid volume is recommended if used during pregnancy. No specific fetal monitoring required beyond routine prenatal care. |
| Fertility Effects | Omalizumab has no known adverse effects on fertility in animal studies. In humans, no data suggest impairment of male or female fertility. It is used in women of childbearing potential without specific restrictions. |